Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care
Objectives. The purpose of this study was to explore the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on urine albumin to creatinine ratio (UACR) in type 2 diabetes mellitus (T2DM) patients and to recommend appropriate medication care scheme. Methods. 8371 T2DM patients from four da...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2022/5854200 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832555193736101888 |
|---|---|
| author | Dong-Dong Wang Cun Zhang Yang Yang Su-Mei He Ping Zhu Xiao Chen |
| author_facet | Dong-Dong Wang Cun Zhang Yang Yang Su-Mei He Ping Zhu Xiao Chen |
| author_sort | Dong-Dong Wang |
| collection | DOAJ |
| description | Objectives. The purpose of this study was to explore the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on urine albumin to creatinine ratio (UACR) in type 2 diabetes mellitus (T2DM) patients and to recommend appropriate medication care scheme. Methods. 8371 T2DM patients from four dapagliflozin studies and two canagliflozin studies were collected for analyzing with nonlinear mixed effect model (NONMEM). The change rates of UACR from baseline were intended to be evaluation indicators. Results. In the present study, there was no significant difference in the effects on UACR using dapagliflozin or canagliflozin treatment in T2DM patients. The maximal effect (Emax) and the treatment duration of reaching half of Emax (ET50) from SGLT-2 inhibitors on UACR in T2DM patients were -19.2% and 0.448 weeks, respectively. Further, the treatment duration to reach 25%, 50%, 75%, and 80% Emax was 0.150 weeks, 0.448 weeks, 1.344 weeks, and 1.792 weeks, respectively. Namely, for achieving the plateau period (80% of Emax) of SGLT-2 inhibitors on UACR in T2DM patients, 10 mg/day dapagliflozin (or 100 mg/day canagliflozin) should be taken for at least 1.792 weeks. Conclusions. To our knowledge, the present study explored the effects of SGLT-2 inhibitors on UACR in T2DM patients, meanwhile, recommended appropriate medication care scheme for the first time. |
| format | Article |
| id | doaj-art-972413b7a0eb4e8e8ae00653721efede |
| institution | Kabale University |
| issn | 2314-6753 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-972413b7a0eb4e8e8ae00653721efede2025-02-03T05:49:21ZengWileyJournal of Diabetes Research2314-67532022-01-01202210.1155/2022/5854200Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication CareDong-Dong Wang0Cun Zhang1Yang Yang2Su-Mei He3Ping Zhu4Xiao Chen5Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy & School of PharmacyDepartment of PharmacyDepartment of PharmacyDepartment of PharmacyDepartment of EndocrinologySchool of NursingObjectives. The purpose of this study was to explore the effects of sodium-glucose cotransporter-2 (SGLT-2) inhibitors on urine albumin to creatinine ratio (UACR) in type 2 diabetes mellitus (T2DM) patients and to recommend appropriate medication care scheme. Methods. 8371 T2DM patients from four dapagliflozin studies and two canagliflozin studies were collected for analyzing with nonlinear mixed effect model (NONMEM). The change rates of UACR from baseline were intended to be evaluation indicators. Results. In the present study, there was no significant difference in the effects on UACR using dapagliflozin or canagliflozin treatment in T2DM patients. The maximal effect (Emax) and the treatment duration of reaching half of Emax (ET50) from SGLT-2 inhibitors on UACR in T2DM patients were -19.2% and 0.448 weeks, respectively. Further, the treatment duration to reach 25%, 50%, 75%, and 80% Emax was 0.150 weeks, 0.448 weeks, 1.344 weeks, and 1.792 weeks, respectively. Namely, for achieving the plateau period (80% of Emax) of SGLT-2 inhibitors on UACR in T2DM patients, 10 mg/day dapagliflozin (or 100 mg/day canagliflozin) should be taken for at least 1.792 weeks. Conclusions. To our knowledge, the present study explored the effects of SGLT-2 inhibitors on UACR in T2DM patients, meanwhile, recommended appropriate medication care scheme for the first time.http://dx.doi.org/10.1155/2022/5854200 |
| spellingShingle | Dong-Dong Wang Cun Zhang Yang Yang Su-Mei He Ping Zhu Xiao Chen Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care Journal of Diabetes Research |
| title | Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care |
| title_full | Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care |
| title_fullStr | Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care |
| title_full_unstemmed | Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care |
| title_short | Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Urine Albumin to Creatinine Ratio in Type 2 Diabetes Mellitus Patients and Medication Care |
| title_sort | effects of sodium glucose cotransporter 2 inhibitors on urine albumin to creatinine ratio in type 2 diabetes mellitus patients and medication care |
| url | http://dx.doi.org/10.1155/2022/5854200 |
| work_keys_str_mv | AT dongdongwang effectsofsodiumglucosecotransporter2inhibitorsonurinealbumintocreatinineratiointype2diabetesmellituspatientsandmedicationcare AT cunzhang effectsofsodiumglucosecotransporter2inhibitorsonurinealbumintocreatinineratiointype2diabetesmellituspatientsandmedicationcare AT yangyang effectsofsodiumglucosecotransporter2inhibitorsonurinealbumintocreatinineratiointype2diabetesmellituspatientsandmedicationcare AT sumeihe effectsofsodiumglucosecotransporter2inhibitorsonurinealbumintocreatinineratiointype2diabetesmellituspatientsandmedicationcare AT pingzhu effectsofsodiumglucosecotransporter2inhibitorsonurinealbumintocreatinineratiointype2diabetesmellituspatientsandmedicationcare AT xiaochen effectsofsodiumglucosecotransporter2inhibitorsonurinealbumintocreatinineratiointype2diabetesmellituspatientsandmedicationcare |